A ma­jor new in­vestor just ar­rived at the biotech par­ty, as Evotec nets $295M from Mubadala and No­vo

Ger­many’s Evotec has a new mi­nor­i­ty stake­hold­er, one that’s pro­vid­ing a hefty heap­ing of ini­tial cash.

Mubadala In­vest­ment Com­pa­ny, the UAE’s sov­er­eign wealth fund, has ac­quired $236 mil­lion worth of shares in a pri­vate place­ment, good for about 5.6% of the com­pa­ny. The fund pur­chased the shares at $25.67, with Evotec giv­ing Mubadala a 3.4% dis­count on its price at mar­ket close Mon­day.

In ad­di­tion, ex­ist­ing in­vestor No­vo in­creased its stake in Evotec to 11% by chip­ping in an­oth­er $59 mil­lion. That brings the to­tal sum raised to about $295 mil­lion, or €250 mil­lion flat.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER